For PwC, ops and business strengths drive PRTM buy

Drug process and regulatory expert PRTM will be acquired by global consultancy PricewaterhouseCoopers. PRTM will join the PwC global advisory practice, among the world's largest consultancies. PwC cites operational strategy, execution and business model innovation among PRTM's strengths, which were no doubt attractive also to drugmaker Ranbaxy when it hired the consultancy to help extricate itself from regulatory hot water. Announcement

Suggested Articles

Colorado is making a play for a Japanese CDMO in hopes it will invest about $100 million in an empty AstraZeneca plant in Boulder.

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.